Telix commences dosing in Phase 3 trial for recurrent glioblastoma
Telix Pharmaceuticals (NASDAQ:TLX) has reached a critical clinical milestone with the dosing of the first patient in its pivotal Phase 3 IPAX BrIGHT trial.
Telix Pharmaceuticals (NASDAQ:TLX) has reached a critical clinical milestone with the dosing of the first patient in its pivotal Phase 3 IPAX BrIGHT trial.
Mesoblast (NASDAQ:MESO) has expanded its advanced therapy pipeline by acquiring an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform.
eToro (NASDAQ:ETOR) announced on Wednesday, April 15, 2026, that it has entered into a definitive agreement to acquire Zengo, a leading provider of self-custodial crypto wallets.
Magnum Mining and Exploration (ASX:MGU) appointed Antonio Vitor Junior as managing director.
EV Resources (ASX:EVR) has defined a laterally extensive, shallow carbonate replacement-style antimony system at its Los Lirios Project.
ReNerve (ASX:RNV) has advanced its NervAlign Nerve Guide Matrix to Stage 3 commercial production.
Nagambie Resources (ASX:NAG) announced a $9 million reduction in total debt, marking a shift in the company’s financial structure.
Xenitra (ASX:XEN) announced the 100% acquisition of Hong Kong Fukang Trading.
QEM (ASX:QEM) announced the strategic acquisition of past-producing fluorspar, tungsten, and niobium projects in Idaho.
OD6 Metals (ASX:OD6) reported ultra-high-grade channel sampling results from the Horseshoe prospect at its Quinn Fluorspar Project.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
